Literature DB >> 27447476

Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in the Elderly: Long-Term Outcomes and Microbiota Changes.

Mohit Girotra1,2, Shashank Garg1,3, Rohit Anand1, Yang Song1,4, Sudhir K Dutta5,6.   

Abstract

BACKGROUND AND AIMS: Fecal microbiota transplantation (FMT) has become the cornerstone in management of recurrent Clostridium difficile infection (RCDI) in adults. However, data on efficacy, safety, long-term outcomes, and microbiota alterations are limited in elderly patients (>65 years).
METHODS: Twenty-nine consecutive elderly patients with RCDI underwent FMT with combined jejunal and colonic method and monitored for long-term outcomes. Fecal samples from five elderly RCDI patients (G65) were subjected to genomic analysis before and after FMT, and microbiota changes were compared with matched RCDI patients below 65 years (L65).
RESULTS: FMT resulted in marked improvement in all clinical parameters, including abdominal pain, bloating, and diarrhea in all elderly RCDI patients. Fecal C. difficile toxin was positive in all 29 patients and turned negative in all 27 patients, who agreed to undergo this test after FMT. Statistically significant improvement in leukocytosis was noted (p < 0.05). Only adverse events reported were transient mild fever (2/29) and bloating (3/29). Long-term follow-up over 25.4 ± 12.8 months did not reveal any additional adverse events or RCDI recurrence. Genomic analysis suggested that overall microbiota diversity increased post-FMT in elderly RCDI patients. However, this response was less robust than the younger group. While Firmicutes did not change markedly, Proteobacteria decreased significantly in post-FMT samples in elderly RCDI patients.
CONCLUSIONS: These observations suggest that FMT in elderly patients with RCDI appears to be highly efficacious with no recurrence of infection over long-term follow-up. Alterations in microbiota in this group of patients are characterized by less robust increase in microbial diversity and marked reduction in phylum Proteobacteria.

Entities:  

Keywords:  Clostridium difficile; Colonic; Efficacy; Elderly; Fecal microbiota transplantation; Geriatric; Jejunal; Outcomes; Safety

Mesh:

Substances:

Year:  2016        PMID: 27447476     DOI: 10.1007/s10620-016-4229-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

1.  A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.

Authors:  Kathleen Machiels; Marie Joossens; João Sabino; Vicky De Preter; Ingrid Arijs; Venessa Eeckhaut; Vera Ballet; Karolien Claes; Filip Van Immerseel; Kristin Verbeke; Marc Ferrante; Jan Verhaegen; Paul Rutgeerts; Séverine Vermeire
Journal:  Gut       Date:  2013-09-10       Impact factor: 23.059

Review 2.  Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection.

Authors:  Ethan Gough; Henna Shaikh; Amee R Manges
Journal:  Clin Infect Dis       Date:  2011-11       Impact factor: 9.079

Review 3.  Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review.

Authors:  Dimitri Drekonja; Jon Reich; Selome Gezahegn; Nancy Greer; Aasma Shaukat; Roderick MacDonald; Indy Rutks; Timothy J Wilt
Journal:  Ann Intern Med       Date:  2015-05-05       Impact factor: 25.391

Review 4.  Ageing and gut microbes: perspectives for health maintenance and longevity.

Authors:  Elena Biagi; Marco Candela; Silvia Turroni; Paolo Garagnani; Claudio Franceschi; Patrizia Brigidi
Journal:  Pharmacol Res       Date:  2012-10-16       Impact factor: 7.658

5.  Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection.

Authors:  Eero Mattila; Raija Uusitalo-Seppälä; Maarit Wuorela; Laura Lehtola; Heimo Nurmi; Matti Ristikankare; Veikko Moilanen; Kimmo Salminen; Maaria Seppälä; Petri S Mattila; Veli-Jukka Anttila; Perttu Arkkila
Journal:  Gastroenterology       Date:  2011-12-07       Impact factor: 22.682

6.  Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.

Authors:  Lawrence J Brandt; Olga C Aroniadis; Mark Mellow; Amy Kanatzar; Colleen Kelly; Tina Park; Neil Stollman; Faith Rohlke; Christina Surawicz
Journal:  Am J Gastroenterol       Date:  2012-03-27       Impact factor: 10.864

7.  Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease.

Authors:  Wei Wang; Liping Chen; Rui Zhou; Xiaobing Wang; Lu Song; Sha Huang; Ge Wang; Bing Xia
Journal:  J Clin Microbiol       Date:  2013-11-13       Impact factor: 5.948

8.  Cultivable and pyrosequenced fecal microflora in centenarians and young subjects.

Authors:  Lorenzo Drago; Marco Toscano; Valentina Rodighiero; Elena De Vecchi; Giovanni Mogna
Journal:  J Clin Gastroenterol       Date:  2012-10       Impact factor: 3.062

9.  Statistical methods for detecting differentially abundant features in clinical metagenomic samples.

Authors:  James Robert White; Niranjan Nagarajan; Mihai Pop
Journal:  PLoS Comput Biol       Date:  2009-04-10       Impact factor: 4.475

10.  Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection.

Authors:  Yang Song; Shashank Garg; Mohit Girotra; Cynthia Maddox; Erik C von Rosenvinge; Anand Dutta; Sudhir Dutta; W Florian Fricke
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

View more
  22 in total

Review 1.  The Present Status of Fecal Microbiota Transplantation and Its Value in the Elderly.

Authors:  Yao-Wen Cheng; Monika Fischer
Journal:  Curr Treat Options Gastroenterol       Date:  2017-09

Review 2.  Antibiotics, gut microbiota, environment in early life and type 1 diabetes.

Authors:  Youjia Hu; F Susan Wong; Li Wen
Journal:  Pharmacol Res       Date:  2017-02-07       Impact factor: 7.658

3.  Fecal Microbiome Among Nursing Home Residents with Advanced Dementia and Clostridium difficile.

Authors:  Rafael Araos; Nikolaos Andreatos; Juan Ugalde; Susan Mitchell; Eleftherios Mylonakis; Erika M C D'Agata
Journal:  Dig Dis Sci       Date:  2018-03-28       Impact factor: 3.199

Review 4.  Fecal microbial transplant for the treatment of pediatric inflammatory bowel disease.

Authors:  Alice Yuxin Wang; Jelena Popov; Nikhil Pai
Journal:  World J Gastroenterol       Date:  2016-12-21       Impact factor: 5.742

5.  An evaluation of the therapeutic potential of fecal microbiota transplantation to treat infectious and metabolic diseases.

Authors:  Albert K Groen; Max Nieuwdorp
Journal:  EMBO Mol Med       Date:  2017-01       Impact factor: 12.137

6.  Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis.

Authors:  Ahmet Uygun; Kadir Ozturk; Hakan Demirci; Cem Oger; Ismail Yasar Avci; Turker Turker; Mustafa Gulsen
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

7.  Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis.

Authors:  Sezin Günaltay; Lech Rademacher; Elisabeth Hultgren Hörnquist; Johan Bohr
Journal:  World J Gastroenterol       Date:  2017-02-21       Impact factor: 5.742

Review 8.  Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity.

Authors:  Christian Carlucci; Elaine O Petrof; Emma Allen-Vercoe
Journal:  EBioMedicine       Date:  2016-10-01       Impact factor: 8.143

9.  Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial.

Authors:  Maja Skov Kragsnaes; Jens Kjeldsen; Hans Christian Horn; Heidi Lausten Munk; Finn Moeller Pedersen; Hanne Marie Holt; Jens Kristian Pedersen; Dorte Kinggaard Holm; Henning Glerup; Vibeke Andersen; Ulrich Fredberg; Karsten Kristiansen; Robin Christensen; Torkell Ellingsen
Journal:  BMJ Open       Date:  2018-04-27       Impact factor: 2.692

Review 10.  Application of Microbiome Management in Therapy for Clostridioides difficile Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents.

Authors:  Chun-Wei Chiu; Pei-Jane Tsai; Ching-Chi Lee; Wen-Chien Ko; Yuan-Pin Hung
Journal:  Pathogens       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.